SPINVERSE AB

Their core work

Spinverse AB is a Stockholm-based innovation consultancy that helps research consortia with project management, commercialization strategy, and industry engagement in EU-funded projects. Their involvement spans wildly different technical domains — from MEMS energy harvesting to nanopharmaceuticals to biorefinery — which is the signature pattern of a service provider rather than a domain-specific R&D performer. They typically join projects as a third party, contributing business development, dissemination, or exploitation planning rather than core technical work.

What they specialise in

How they've shifted over time

Spinverse AB's early H2020 involvement (2014-2016) focused on hardware and electronics — specifically MEMS-based energy harvesting and nanopharmaceutical manufacturing pilots. From 2017 onward, their projects shifted toward biomedical devices (optogenetics for Parkinson's disease) and bioeconomy (lignin-based biorefinery), reflecting the broader EU funding pivot toward health and green industry. The lack of early-period keywords in the data suggests their initial contributions were more generic (project management, dissemination) while later projects involved more domain-specific commercialization support.

Moving toward green industry and health technology commercialization support, aligning with EU Green Deal and health mission priorities.

How they like to work

Spinverse AB operates almost exclusively as a third party (3 of 4 projects), meaning they are brought in by consortium members for specific support tasks rather than being a core proposal partner. Despite this peripheral formal role, they have connected with 34 unique partners across 12 countries, indicating broad network exposure. This is typical of innovation consultancies — they touch many projects lightly rather than embedding deeply in a few, making them useful connectors but not long-term technical collaborators.

Connected to 34 unique consortium partners across 12 countries through just 4 projects, reflecting the large consortia typical of RIA/IA projects and Spinverse's role as a service provider with broad but shallow network ties.

What sets them apart

Spinverse AB's value lies in their sector-agnostic innovation management capability — they can support commercialization planning whether the technology is a MEMS sensor or a lignin biorefinery. For consortium builders, they offer a ready-made partner for exploitation work packages who already understands EU project mechanics. However, their very low direct EC funding (EUR 45,000 total) and predominant third-party status mean they are best suited as a lightweight support partner, not a work package leader.

Highlights from their portfolio

• SWEETWOODS
  Their most recent and longest-running involvement (2018-2024), focused on lignin valorization — a high-priority EU bioeconomy topic with strong industrial demand.
• STARDUST
  Combines optogenetics, implantable devices, and Parkinson's treatment — an ambitious convergence of neuroscience and microelectronics where commercialization support is critical.